A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504288-18-00

Acronym

DF-006-1001

Enrollment

Registered

2024-04-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis B

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Bulgaria, Romania

None listed

Source: EU CTIS · Data processed: Feb 4, 2026